Proliferating fraction during neoadjuvant chemotherapy of primary breast cancer in relation to objective local response and relapse-free survival

Acta Oncologica

Volumn 38, Issue 5, 1999, Pages 597-601

  Billgren, Ann Marie ^a   Rutqvist, Lars Erik ^b   Tani, Edneia ^b   Wilking, Nils ^b   Fornander, Tommy ^b   Skoog, Lambert ^b  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; EPIRUBICIN; FLUOROURACIL; KI 67 ANTIGEN;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; BREAST BIOPSY; BREAST CANCER; CANCER RECURRENCE; CANCER SURVIVAL; CELL PROLIFERATION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOPEROXIDASE STAINING; MAJOR CLINICAL STUDY; MASTECTOMY; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROGNOSIS;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CELL DIVISION; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; EPIRUBICIN; FEMALE; FLUOROURACIL; HUMANS; KI-67 ANTIGEN; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM RECURRENCE, LOCAL; PATIENT SELECTION; PREDICTIVE VALUE OF TESTS; PROGNOSIS; TREATMENT OUTCOME;

EID: 0032866179     PISSN: 0284186X     EISSN: None     Source Type: Journal    
DOI: 10.1080/028418699431186     Document Type: Article

References (19)

1. 1. Bonnadonna G, Valagussa P, Zukali R, Salvadori B. Primary chemotherapy in surgically resectable breast cancer. CA A Cancer J Clin 1995; 45: 227-43.
2. 2. Remvikos Y, Beuzeboc P, Zajdela A, Voillemont N, Magdelénat H, Pouillart P. Correlation of pretreatment proliferative activity of breast cancer with response to cytotoxic chemotherapy. J Natl Cancer Inst 1989; 81: 1383-6.
3. 3. Chevillard S, Pouillart P, Beldjord C, et al. Sequentional assessment of multidrug resistance phenotype and measurement or S-phase as predictive markers of breast cancer response to neoadjuvant chemotherapy. Cancer 1996; 77: 292-300.
4. 4. Bonetti A, Zaninelli M, Rodella S, et al. Tumor proliferative activity and response to first-line chemotherapy in advanced breast carcinoma. Breast Cancer Res Treatment 1996; 38: 289-97.
5. 5. Fisher B, Gunduz N, Constantino J, Fisher E, Redmond C. DNA flow cytometric analysis of primary operable breast cancer. Cancer 1991; 68: 1465-75.
6. 6. Clayton F. Pathologic correlates of survival in 378 lymph node-negative infiltrating ductal breast carcinomas. Cancer 1991; 68: 1309-17.
7. 7. Merkel D, Winchester D, Goldschmidt R, August C, Wruck D, Rademaker A. DNA flow cytometry and pathologic grading as prognostic guides in axillary lymph node-negative breast cancer. Cancer 1993; 72: 1926-31.
8. 8. Tahan S, Neuberg D, Dieffenbach A, Yacoub L. Prediction of early relapse and shortened survival in patients with breast cancer by proliferating cell nuclear antigen score. Cancer 1993; 71: 3552-9.
9. 9. Bianchi S, Paglierani M, Zampi G, et al. Prognostic value of proliferating cell nuclear antigen in lymph node-negative breast cancer patients. Cancer 1993; 72: 120-5.
10. 10. Pisanski T, Ingle J, Schaid D, et al. Patterns of tumor relapse following mastectomy and adjuvant systemic therapy in patients with axillary lymph node-positive breast cancer. Cancer 1993; 72: 1247-60.
11. 11. Skoog L, Humla S, Isaksson S, Tani E. Immunocytochemical analysis of receptors for estrogen and progesterone in fine-needle aspirates from human breast carcinomas. Digan Cytopathol 1990; 6: 95-8.
12. 12. Söderqvist G, Isaksson E, von Schoultz B, Carlström K, Tani E, Skoog L. Proliferation of breast epithelial cells in healthy women during the menstrual cycle. Am J Obstet Gynecol 1996; 176: 123-8.
13. 13. Zaijzek J. Aspiration biopsy cytology. Part 1. In: Wied GL, ed. Cytology of supradiaphragmatic organs in monographs in clinical cytology. 4th vol. Basel: S Karger, 1974.
14. 14. Gerdes J, et al. Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J Cancer 1983; 31: 13-20.
15. 15. Skoog I, Wilking N, Humla S, Stenqvist B, Rutqvist L-E. Immunocytochemical analysis of receptors for estrogen and progesterone in fine needle aspirates from primary breast carcinomas during tamoxifen treatment. Diagn Oncol 1991; 1: 282-7.
16. 16. Gardin G, Alama A, Rosso R, et al. Relationship of variations in cell kinetics induced by primary chemotherapy to tumor regression and prognosis in locally advanced breast cancer. Breast Cancer Res Treatment 1994; 32: 311-8.
17. 17. Daidone MG, Silvestrini R, Valentinis B, Ferrari L, Bartoli C. Changes in cell kinetics induced by primary chemotherapy in breast cancer. Int J Cancer 1991; 47: 380-3.
18. 18. Fisher E, Brown A, Mamounas E, et al. Effect of preoperative therapy for primary breast cancer (BC) on loco-regional disease, disease-free survival (DFS) and survival (S): results from NSABP-18. Proceedings of ASCO 1997; 18: 172a.
19. 19. Lee A, Wiley B, Dugan J, et al. Quantitative DNA analysis and proliferation in breast carcinomas. Path Res Pract 1992; 188: 428-32.